bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation
Authors: Michmerhuizen Anna R. , Pesch Andrea M. , Moubadder Leah , Chandler Benjamin C. , Wilder-Romans Kari , Cameron Meleah , Olsen Eric , Thomas Dafydd G. , Zhang Amanda , Hirsh Nicole , Ritter Cassandra L. , Liu Meilan , Nyati Shyam , Pierce Lori J. , Jagsi Reshma , Speers Corey
Published: April 2023

Ki67 and p16 levels are decreased in tumors from animals treated with radiation and combination PARP-inhibitor and radiation. SUM-190 xenograft tumors that were harvested from mice at the completion of the long-term in vivo study. Protein expression levels were assessed by immunohistochemical staining. Levels of Ki67, a marker of proliferation, are significantly decreased in all treatment groups (A), and p16 levels are significantly decreased in the RT-alone and combination treated groups (B). Representative images from each group are shown (C,D). (* p < 0.05, ** p <0.01, *** p < 0.001)
Figure S2 from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation
Authors: Michmerhuizen Anna R. , Pesch Andrea M. , Moubadder Leah , Chandler Benjamin C. , Wilder-Romans Kari , Cameron Meleah , Olsen Eric , Thomas Dafydd G. , Zhang Amanda , Hirsh Nicole , Ritter Cassandra L. , Liu Meilan , Nyati Shyam , Pierce Lori J. , Jagsi Reshma , Speers Corey
Published: April 2023

Higher doses of olaparib are sufficient to inhibit PAR formation in BRCA1-mutant SUM-149 cells. At higher concentrations of olaparib (1μM), combination treatment of PARP1 inhibition and radiation decreases PAR in a comparable manner to lower doses of olaparib (20nM) in SUM-149 cells.
Figure S1 from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation
Authors: Michmerhuizen Anna R. , Pesch Andrea M. , Moubadder Leah , Chandler Benjamin C. , Wilder-Romans Kari , Cameron Meleah , Olsen Eric , Thomas Dafydd G. , Zhang Amanda , Hirsh Nicole , Ritter Cassandra L. , Liu Meilan , Nyati Shyam , Pierce Lori J. , Jagsi Reshma , Speers Corey
Published: April 2023

Enhancement ratios and toxicity for IBC clonogenic survival assays. Average radiation enhancement ratio (rER) and toxicity values are shown for each treatment in SUM-190 (A), MDA-IBC-3 (B), and SUM-149 (C) cells.
Supplemental Table 1 from Inhibition of Lysosomal Function Mitigates Protective Mitophagy and Augments Ceramide Nanoliposome–Induced Cell Death in Head and Neck Squamous Cell Carcinoma
Authors: Shaw Jeremy J.P. , Boyer Timothy L. , Venner Emily , Beck Patrick J. , Slamowitz Tristen , Caste Tara , Hickman Alexandra , Raymond Michael H. , Costa-Pinheiro Pedro , Jameson Mark J. , Fox Todd E. , Kester Mark
Published: April 2023

Inhibitors and Inducers of Autophagy
Table S4 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

shows plasma analytes associated with the maximum change in tumor area
Supplemental Figure 2 from Inhibition of Lysosomal Function Mitigates Protective Mitophagy and Augments Ceramide Nanoliposome–Induced Cell Death in Head and Neck Squamous Cell Carcinoma
Authors: Shaw Jeremy J.P. , Boyer Timothy L. , Venner Emily , Beck Patrick J. , Slamowitz Tristen , Caste Tara , Hickman Alexandra , Raymond Michael H. , Costa-Pinheiro Pedro , Jameson Mark J. , Fox Todd E. , Kester Mark
Published: April 2023

Inducing or Inhibiting Early Stage Autophagy Does Not Alter CNL-Induced Cell Death in HNSCC
Supplemental Figure 1 from Inhibition of Lysosomal Function Mitigates Protective Mitophagy and Augments Ceramide Nanoliposome–Induced Cell Death in Head and Neck Squamous Cell Carcinoma
Authors: Shaw Jeremy J.P. , Boyer Timothy L. , Venner Emily , Beck Patrick J. , Slamowitz Tristen , Caste Tara , Hickman Alexandra , Raymond Michael H. , Costa-Pinheiro Pedro , Jameson Mark J. , Fox Todd E. , Kester Mark
Published: April 2023

IC50 Values of CNL-Induced Decreases in Cell Viability at 48 hours in Seven HNSCC Cell Lines and Non-Transformed PGF Cells.
Supplementary materials and methods from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

Shows supplementary methods
Figure S3 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

shows copanlisib plasma concentration over time following infusion during the first week
Figure S2 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

shows changes in plasma levels of metabolic and immune cell markers following treatment with copanlisib
Figure S1 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

shows mean systolic blood pressure in patients receiving copanlisib over the first 24 hours
Supplementary Text from Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Authors: Vijayaraghavan Smruthi , Lipfert Lorraine , Chevalier Kristen , Bushey Barbara S. , Henley Benjamin , Lenhart Ryan , Sendecki Jocelyn , Beqiri Marilda , Millar Hillary J. , Packman Kathryn , Lorenzi Matthew V. , Laquerre Sylvie , Moores Sheri L.
Published: April 2023

Contains Supplementary methods, supp figure legends
Supplementary Movie M4 from Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Authors: Vijayaraghavan Smruthi , Lipfert Lorraine , Chevalier Kristen , Bushey Barbara S. , Henley Benjamin , Lenhart Ryan , Sendecki Jocelyn , Beqiri Marilda , Millar Hillary J. , Packman Kathryn , Lorenzi Matthew V. , Laquerre Sylvie , Moores Sheri L.
Published: April 2023

Live cell imaging of M1 macrophage mediated trogocytosis in adherent co-culture
Supplementary Movie M2 from Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Authors: Vijayaraghavan Smruthi , Lipfert Lorraine , Chevalier Kristen , Bushey Barbara S. , Henley Benjamin , Lenhart Ryan , Sendecki Jocelyn , Beqiri Marilda , Millar Hillary J. , Packman Kathryn , Lorenzi Matthew V. , Laquerre Sylvie , Moores Sheri L.
Published: April 2023

Live cell imaging of M1 macrophage mediated trogocytosis
Supplementary Figures from Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Authors: Vijayaraghavan Smruthi , Lipfert Lorraine , Chevalier Kristen , Bushey Barbara S. , Henley Benjamin , Lenhart Ryan , Sendecki Jocelyn , Beqiri Marilda , Millar Hillary J. , Packman Kathryn , Lorenzi Matthew V. , Laquerre Sylvie , Moores Sheri L.
Published: April 2023

Contains supp figures S1-S13 and the corresponding figure legends
Supplementary Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Authors: Sampera Aïda , Sánchez-Martín Francisco Javier , Arpí Oriol , Visa Laura , Iglesias Mar , Menéndez Sílvia , Gaye Élisabeth , Dalmases Alba , Clavé Sergi , Gelabert-Baldrich Mariona , Poulsen Thomas Tuxen , Kragh Michael , Bellosillo Beatriz , Albanell Joan , Rovira Ana , Montagut Clara
Published: April 2023

Supplementary Figures and Material and Methods
Supplementary Table S1 from CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma
Authors: Flores Guillermo , Everett Joel H. , Boguslawski Elissa A. , Oswald Brandon M. , Madaj Zachary B. , Beddows Ian , Dikalov Sergey , Adams Marie , Klumpp-Thomas Carleen A. , Kitchen-Goosen Susan M. , Martin Scott E. , Caplen Natasha J. , Helman Lee J. , Grohar Patrick J.
Published: April 2023

Primary screening data, Lead candidates and GO analysis
Supplementary Figures from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Authors: Yang Zhenyu , Wang Dan , Johnson James K. , Pascal Laura E. , Takubo Keita , Avula Raghunandan , Chakka Anish Bhaswanth , Zhou Jianhua , Chen Wei , Zhong Mingming , Song Qiong , Ding Hui , Wu Zeyu , Chandran Uma R. , Maskrey Taber S. , Nelson Joel B. , Wipf Peter , Wang Zhou
Published: April 2023

Supplementary Figures S1-S7
Supplementary table from The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
Authors: Sugimoto Yohei , Katsumi Yoshiki , Iehara Tomoko , Kaneda Daisuke , Tomoyasu Chihiro , Ouchi Kazutaka , Yoshida Hideki , Miyachi Mitsuru , Yagyu Shigeki , Kikuchi Ken , Tsuchiya Kunihiko , Kuwahara Yasumichi , Sakai Toshiyuki , Hosoi Hajime
Published: April 2023

Supplementary table
Supplementary Figure 4. from The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
Authors: Sugimoto Yohei , Katsumi Yoshiki , Iehara Tomoko , Kaneda Daisuke , Tomoyasu Chihiro , Ouchi Kazutaka , Yoshida Hideki , Miyachi Mitsuru , Yagyu Shigeki , Kikuchi Ken , Tsuchiya Kunihiko , Kuwahara Yasumichi , Sakai Toshiyuki , Hosoi Hajime
Published: April 2023

Supplementary Figure 4.
Supplementary Figure 3. from The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
Authors: Sugimoto Yohei , Katsumi Yoshiki , Iehara Tomoko , Kaneda Daisuke , Tomoyasu Chihiro , Ouchi Kazutaka , Yoshida Hideki , Miyachi Mitsuru , Yagyu Shigeki , Kikuchi Ken , Tsuchiya Kunihiko , Kuwahara Yasumichi , Sakai Toshiyuki , Hosoi Hajime
Published: April 2023

Supplementary Figure 3.
Supplementary Figure 2. from The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
Authors: Sugimoto Yohei , Katsumi Yoshiki , Iehara Tomoko , Kaneda Daisuke , Tomoyasu Chihiro , Ouchi Kazutaka , Yoshida Hideki , Miyachi Mitsuru , Yagyu Shigeki , Kikuchi Ken , Tsuchiya Kunihiko , Kuwahara Yasumichi , Sakai Toshiyuki , Hosoi Hajime
Published: April 2023

Supplementary Figure 2.
Supplementary Materials and Methods from Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma
Authors: Wei Bih-Rong , Hoover Shelley B. , Peer Cody J. , Dwyer Jennifer E. , Adissu Hibret A. , Shankarappa Priya , Yang Howard , Lee Maxwell , Peat Tyler J. , Figg William D. , Simpson R. Mark
Published: April 2023

Supplemental text file for materials and methods
Supplementary Data from Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma
Authors: Wei Bih-Rong , Hoover Shelley B. , Peer Cody J. , Dwyer Jennifer E. , Adissu Hibret A. , Shankarappa Priya , Yang Howard , Lee Maxwell , Peat Tyler J. , Figg William D. , Simpson R. Mark
Published: April 2023

Supplementary Figures S1 - S7
Supplementary Figures 1-7, Table 1 and Methods. from Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids
Authors: Vernon Mégane , Lambert Bernard , Meryet-Figuière Matthieu , Brotin Emilie , Weiswald Louis-Bastien , Paysant Hippolyte , Vigneron Nicolas , Wambecke Anaïs , Abeilard Edwige , Giffard Florence , Louis Marie-Hélène , Blanc-Fournier Cécile , Gauduchon Pascal , Poulain Laurent , Denoyelle Christophe
Published: April 2023

Supplementary Figure 1 shows that a screening identifies some miRNAs affecting the cell viability of IGROV1-R10 ovarian cancer cell line; Supplementary Figure 2 shows that miR-3622b-5p is poorly expressed in ovarian cancer cells compared to fallopian tubes epithelial cells; Supplementary Figure 3 shows that miR-3622b-5p induces apoptosis in a panel of ovarian cancer cell lines; Supplementary Figure 4 shows that miR-3622b-5p does not sensitize SKOV3 ovarian cancer cell line to platinum; Supplementary Figure 5 shows some targets and associated cell signaling pathways modulated by miR-3622b-5p in several ovarian cancer cell lines; Supplementary Figure 6 shows that miR-3622b-5p sensitizes OAW42-R ovarian chemoresistant cancer cells to cisplatin; Supplementary Figure 7 shows some targets regulated by miR-3622b-5p in SKOV3 cells; Supplementary Table 1 describes the antibodies and the oligonucleotides used in this study.
Supplementary Data from An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells
Authors: Dong Ruochen , Chen Ping , Polireddy Kishore , Wu Xiaoqing , Wang Tao , Ramesh Remya , Dixon Dan A. , Xu Liang , Aubé Jeffrey , Chen Qi
Published: April 2023

Supplementary Data
Figure S7 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
Authors: Makdasi Efi , Amsili Shira , Aronin Alexandra , Prigozhina Tatyana B. , Tzdaka Kobi , Gozlan Yosi Meir , Ben Gigi–Tamir Liat , Sagiv Jitka Yehudith , Shkedy Fanny , Shani Noam , Tykocinski Mark L. , Dranitzki Elhalel Michal
Published: April 2023

Increased susceptibility of monkey PBMCs to CTLA4-FasL and sFasL treatments compared to human PBMCs
Figure S6 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
Authors: Makdasi Efi , Amsili Shira , Aronin Alexandra , Prigozhina Tatyana B. , Tzdaka Kobi , Gozlan Yosi Meir , Ben Gigi–Tamir Liat , Sagiv Jitka Yehudith , Shkedy Fanny , Shani Noam , Tykocinski Mark L. , Dranitzki Elhalel Michal
Published: April 2023

Transient and reversible decrease of lymphocytes subpopulations in treated monkeys
Figure S5 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
Authors: Makdasi Efi , Amsili Shira , Aronin Alexandra , Prigozhina Tatyana B. , Tzdaka Kobi , Gozlan Yosi Meir , Ben Gigi–Tamir Liat , Sagiv Jitka Yehudith , Shkedy Fanny , Shani Noam , Tykocinski Mark L. , Dranitzki Elhalel Michal
Published: April 2023

Elevation of pro-inflammatory cytokines in CTLA4-FasL treated monkeys was prevented by dexamethasone
Figure S3 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
Authors: Makdasi Efi , Amsili Shira , Aronin Alexandra , Prigozhina Tatyana B. , Tzdaka Kobi , Gozlan Yosi Meir , Ben Gigi–Tamir Liat , Sagiv Jitka Yehudith , Shkedy Fanny , Shani Noam , Tykocinski Mark L. , Dranitzki Elhalel Michal
Published: April 2023

Elevated globulin and no significant increase in liver enzyme levels in CTLA4-FasL treated mice
Figure S2 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
Authors: Makdasi Efi , Amsili Shira , Aronin Alexandra , Prigozhina Tatyana B. , Tzdaka Kobi , Gozlan Yosi Meir , Ben Gigi–Tamir Liat , Sagiv Jitka Yehudith , Shkedy Fanny , Shani Noam , Tykocinski Mark L. , Dranitzki Elhalel Michal
Published: April 2023

Transient changes in blood counts in CTLA4-FasL treated mice were prevented by dexamethasone
Supplementary Text 1 from Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Authors: Krook Melanie A. , Lenyo Alexandria , Wilberding Max , Barker Hannah , Dantuono Mikayla , Bailey Kelly M. , Chen Hui-Zi , Reeser Julie W. , Wing Michele R. , Miya Jharna , Samorodnitsky Eric , Smith Amy M. , Dao Thuy , Martin Dorrelyn M. , Ciombor Kristen K. , Hays John , Freud Aharon G. , Roychowdhury Sameek
Published: April 2023

Sequence for the FGFR2-KIAA1598 fusion
Figure S1 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
Authors: Makdasi Efi , Amsili Shira , Aronin Alexandra , Prigozhina Tatyana B. , Tzdaka Kobi , Gozlan Yosi Meir , Ben Gigi–Tamir Liat , Sagiv Jitka Yehudith , Shkedy Fanny , Shani Noam , Tykocinski Mark L. , Dranitzki Elhalel Michal
Published: April 2023

(a) Receptors expression on human cell lines and mouse BCL-1 splenocytes. (b) Anti CTLA4-FasL antibodies are formed in treated mice. (c) Neutralizing anti CTLA4-FasL antibodies are formed in treated mice.
Supplementary Table 1 from Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Authors: Krook Melanie A. , Lenyo Alexandria , Wilberding Max , Barker Hannah , Dantuono Mikayla , Bailey Kelly M. , Chen Hui-Zi , Reeser Julie W. , Wing Michele R. , Miya Jharna , Samorodnitsky Eric , Smith Amy M. , Dao Thuy , Martin Dorrelyn M. , Ciombor Kristen K. , Hays John , Freud Aharon G. , Roychowdhury Sameek
Published: April 2023

Primer sequences used for PCR and Sanger sequencing.
Supplementary Figure 2 from Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Authors: Krook Melanie A. , Lenyo Alexandria , Wilberding Max , Barker Hannah , Dantuono Mikayla , Bailey Kelly M. , Chen Hui-Zi , Reeser Julie W. , Wing Michele R. , Miya Jharna , Samorodnitsky Eric , Smith Amy M. , Dao Thuy , Martin Dorrelyn M. , Ciombor Kristen K. , Hays John , Freud Aharon G. , Roychowdhury Sameek
Published: April 2023

Sensitivity of the FGFR2 secondary mutations to FGFR inhibitors
Supplementary Figure 1 from Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Authors: Krook Melanie A. , Lenyo Alexandria , Wilberding Max , Barker Hannah , Dantuono Mikayla , Bailey Kelly M. , Chen Hui-Zi , Reeser Julie W. , Wing Michele R. , Miya Jharna , Samorodnitsky Eric , Smith Amy M. , Dao Thuy , Martin Dorrelyn M. , Ciombor Kristen K. , Hays John , Freud Aharon G. , Roychowdhury Sameek
Published: April 2023

Sequence for FGFR2-KIAA1598 fusion.
Fig S1-4; Table S1, S2, S4 and S5; S methods from Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer
Authors: Al Amri Waleed S. , Allinson Lisa M. , Baxter Diana E. , Bell Sandra M. , Hanby Andrew M. , Jones Stacey J. , Shaaban Abeer M. , Stead Lucy F. , Verghese Eldo T. , Hughes Thomas A.
Published: April 2023

Supplementary information concerning: laser capture microscopy (Fig S1), efficiency of siRNA knock-down (Fig S2), results of siRNA knock-down for ABC gene expression and function (Fig S3), abilities of MUC17 and PCNX1 expression to define patient outcomes (Fig S4), patient characteristics (Table S1), sequencing metrics (Table S2), statistical parameters (Tables S4 and S5) and supplementary methods.
Supplementary Figure S1_S4 from Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin
Authors: Yang Bing , Damodaran Shivashankar , Khemees Tariq A. , Filon Mikolaj J. , Schultz Adam , Gawdzik Joseph , Etheridge Tyler , Malin Dmitry , Richards Kyle A. , Cryns Vincent L. , Jarrard David F.
Published: April 2023

All supplementery figures
Supplementary Data - Figures and Legends from Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer
Authors: Song Heyu , Zeng Jiping , Roychoudhury Shrabasti , Biswas Pranjal , Mohapatra Bhopal , Ray Sutapa , Dowlatshahi Kayvon , Wang Jing , Band Vimla , Talmon Geoffrey , Bhakat Kishor K.
Published: April 2023

Figure S1. IC50 decreased after APE1 knockdown. Figure S2. MMS increased colocalization of APE1 and FACT complex. Figure S3. FACT knockdown did not affect total APE1 level but decreased the occupancy of APE1 to p21 and DTL promoters. Figure S4. CBL0137 had minimal toxicity on cells. Figure S5. Combination of 5-FU and curaxins significantly inhibited xenograft growth. Figure S6. High expression of AcAPE1 and SSRP1 was observed in dMMR patients.
Supplementary Data: Figure S1-3 and Table S1-S5 from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts
Authors: Abu-Yousif Adnan O. , Cvet Donna , Gallery Melissa , Bannerman Bret M. , Ganno Michelle L. , Smith Michael D. , Lai Katharine C. , Keating Thomas A. , Stringer Bradley , Kamali Afrand , Eng Kurt , Koseoglu Secil , Zhu Andy , Xia Cindy Q. , Landen Melissa Saylor , Borland Maria , Robertson Robbie , Bolleddula Jayaprakasam , Qian Mark G. , Fretland Jennifer , Veiby O. Petter
Published: April 2023

Supplemental Figure 1: heavy and light chain sequences for 5F9, the human IgG1 monoclonal antibody (mAb) targeting the extracellular domain of GCC as described previously Supplemental Figure 2: Characterization of TAK-164 and chKTI-DGN549 by A) SDS PAGE gel and B) by Liquid chromatography-mass spectrometry (LC-MS) Supplemental Figure 3: In vivo activity of TAK-164 in PHTXM-46C Supplemental Table 1: Growth rate inhibition following treatment with TAK-164 and B) chKTI-ADC in PHTX and cell derived xenograft models Supplemental Table 2: Growth Rate Inhibition and associated statistics for HEK293 GCC#2 Supplemental Table 3: Growth Rate Inhibition and associated statistics for PHTX-09C Supplemental Table 4: Growth Rate Inhibition and associated statistics for PHTX-17C Supplemental Table 5: Growth Rate Inhibition and associated statistics for PHTX-11C
Supplementary Tables from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Authors: Varghese Sruthy , Pramanik Snigdha , Williams Leila J. , Hodges Hannah R. , Hudgens Courtney W. , Fischer Grant M. , Luo Catherine K. , Knighton Barbara , Tan Lin , Lorenzi Philip L. , Mackinnon Andrew L. , McQuade Jennifer L. , Hailemichael Yared , Roszik Jason , Peng Weiyi , Vashisht Gopal Y.N.
Published: April 2023

Supplementary tables
Supplementary Methods from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Authors: Varghese Sruthy , Pramanik Snigdha , Williams Leila J. , Hodges Hannah R. , Hudgens Courtney W. , Fischer Grant M. , Luo Catherine K. , Knighton Barbara , Tan Lin , Lorenzi Philip L. , Mackinnon Andrew L. , McQuade Jennifer L. , Hailemichael Yared , Roszik Jason , Peng Weiyi , Vashisht Gopal Y.N.
Published: April 2023

Supplementary Methods
Supplementary Materials and Methods from Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA
Authors: Orozco Johnnie J. , Kenoyer Aimee L. , Lin Yukang , O'Steen Shyril , Guel Rosario , Nartea Margaret E. , Hernandez Alexandra H. , Hylarides Mark D. , Fisher Darrell R. , Balkin Ethan R. , Hamlin Donald K. , Wilbur D. Scott , Orcutt Kelly D. , Wittrup K. Dane , Green Damian J. , Gopal Ajay K. , Till Brian G. , Sandmaier Brenda , Press Oliver W. , Pagel John M.
Published: April 2023

Supplementary Materials, Methods and relevant AA sequences
Supplementary Materials and Methods, Supplementary Tables 1--4 and Supplementary Figures 1-4 from Preclinical Characterization of an Antibody–Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1–Positive Cells
Authors: Chen Ruoyan , Rajan Saravanan , Overstreet Michael G. , Hurt Elaine M. , Thomas Suneetha B. , Muniz-Medina Vanessa , Ward Christopher , Sadowska Agnieszka , Fleming Ryan , Karanth Subramanya , Breen Shannon , Zheng Bo , Wu Yuling , Iverson William O. , Novick Steven , O'Day Terrence , Shah Dipesha P. , Dimasi Nazzareno , Tiberghien Arnaud C. , Osbourn Jane , Walker Jill
Published: April 2023

Supplementary Materials and Methods, Supplementary Table S1. Sources of cell lines and cell growth media; Supplemental Table S2. Sources of antibodies for flow cytometry; Supplementary Table S3. CS-1 ADC Characteristics, Supplemental Table S4. Pharmacokinetic profile of the CS-1 ADC; Supplemental Figure S1. Characterization of the CS-1 ADC molecule; Supplemental Figure S2. CS-1 ADC effect on tumor cell growth; Figure S3. Detailed results of colony forming assays; Supplementary Figure S4. CS-1 mAb and elotuzumab bind to similar cells in bone marrow.
Supplementary Data from Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2
Authors: Li Qiaqia , Liu Kilia Y. , Liu Qipeng , Wang Guangyu , Jiang Weihua , Meng Qingshu , Yi Yang , Yang Yongyong , Wang Rui , Zhu Sen , Li Chao , Wu Longxiang , Zhao Dongyu , Yan Lin , Zhang Lili , Kim Jung-Sun , Zu Xiongbing , Kozielski Anthony J. , Qian Wei , Chang Jenny C. , Patnaik Akash , Chen Kaifu , Cao Qi
Published: April 2023

Supplementary Data File
Supplementary Figure S5 from High-Throughput Generation of Bispecific Binding Proteins by Sortase A–Mediated Coupling for Direct Functional Screening in Cell Culture
Authors: Andres Fabio , Schwill Martin , Boersma Ykelien L. , Plückthun Andreas
Published: April 2023

Receptor crosslinking and proliferation assay of BT474 cells after treatment
Supplementary Figure S3 from High-Throughput Generation of Bispecific Binding Proteins by Sortase A–Mediated Coupling for Direct Functional Screening in Cell Culture
Authors: Andres Fabio , Schwill Martin , Boersma Ykelien L. , Plückthun Andreas
Published: April 2023

Summary of monovalent DARPins binding to different extracellular subdomains on the indicated receptors
Figure S6 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
Authors: Akbulut Ozge , Lengerli Deniz , Saatci Ozge , Duman Elif , Seker Urartu O.S. , Isik Aynur , Akyol Aytekin , Caliskan Burcu , Banoglu Erden , Sahin Ozgur
Published: April 2023

BO-264 impairs tumor growth better than SPL-B does at the same dose.
Supplementary Figure S1 from High-Throughput Generation of Bispecific Binding Proteins by Sortase A–Mediated Coupling for Direct Functional Screening in Cell Culture
Authors: Andres Fabio , Schwill Martin , Boersma Ykelien L. , Plückthun Andreas
Published: April 2023

Characterization of ErbB3 ECD binding DARPins
Figure S5 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
Authors: Akbulut Ozge , Lengerli Deniz , Saatci Ozge , Duman Elif , Seker Urartu O.S. , Isik Aynur , Akyol Aytekin , Caliskan Burcu , Banoglu Erden , Sahin Ozgur
Published: April 2023

BO-264 significantly suppresses tumor growth in colon cancer models.
Supplementary Materials and Methods, Supplementary 1-7 and Supplementary Table 1. from ERK Inhibition Improves Anti–PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma
Authors: Henry Kelly E. , Mack Kyeara N. , Nagle Veronica L. , Cornejo Mike , Michel Adam O. , Fox Ian L. , Davydova Maria , Dilling Thomas R. , Pillarsetty Nagavarakishore , Lewis Jason S.
Published: April 2023

Supplementary Materials and Methods. Supplementary Figure 1. Fibroblast isolation from orthotopic PDAC tumor microenvironment. Supplementary Figure 2. Controls for immunofluorescence experiments to confirm no cross-reactivity or non-specific binding, and to identify regions to exclude via secondary entrapment. Supplementary Figure 3. Blocking study with [89Zr]Zr-DFO-anti-PD-L1. Supplementary Figure 4. Combination ERK inhibition and anti-PD-L1 does not improve survival in subcutaneous tumors. Supplementary Figure 5. Ex vivo analysis of endpoint tissues suggests immunosuppressive mechanism. Supplementary Figure 6. Immunohistochemical analysis of ex vivo tissues collected at endpoint indicate a potential immunosuppressive mechanism. Supplementary Figure 7. Immunohistochemical analysis of ex vivo tissues collected at single endpoint. Supplementary Table 1. Immunohistochemistry details for TME analysis.
Figure S3 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
Authors: Akbulut Ozge , Lengerli Deniz , Saatci Ozge , Duman Elif , Seker Urartu O.S. , Isik Aynur , Akyol Aytekin , Caliskan Burcu , Banoglu Erden , Sahin Ozgur
Published: April 2023

TACC3 level is critical for BO-264 response.
Figure S1 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
Authors: Akbulut Ozge , Lengerli Deniz , Saatci Ozge , Duman Elif , Seker Urartu O.S. , Isik Aynur , Akyol Aytekin , Caliskan Burcu , Banoglu Erden , Sahin Ozgur
Published: April 2023

Synthesis of BO-264.
Supplementary Table 1-3 and Figures 1-7. from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer
Authors: Wen Yunfei , Wang Ying , Chelariu-Raicu Anca , Stur Elaine , Liu Yuan , Corvigno Sara , Bartsch Faith , Redfern Lauren , Zand Behrouz , Kang Yu , Liu Jinsong , Baggerly Keith , Sood Anil K.
Published: April 2023

Supplementary Materials and Methods, Supplementary Table S1. List of 9 PRLR gene isoforms in the UCSC Genome Browser based on RNASeqV2 data. Supplementary Table S2. Protein expression profile by RPPA analysis in Ishikawa tumors treated with mannitol or G129R. Supplementary Table S3. Pathological staining results for PRLR using 2 scoring metrics in normal uterine tissue (n=3 patients) and UCEC-EEA (n=3 patients). Supplementary Figure S1 (supporting Figure 1). Expression of PRLR_SF (uc003jjl.3) in UCEC-EEA patients. Supplementary Figure S2 (supporting Figure 1). Expression of PRLR in human uterine cancer cell lines with both PTENmut and PTENWT backgrounds. Supplementary Figure S3 (supporting Figure 2). Representative images from the Ishikawa model showed the different sizes of primary tumors at the uterine horn in different groups. Supplementary Figure S4 (supporting Figure 3). In vitro efficacy of G129R in Ishikawa and Hec1-A cells under hormone-depleted condition. Supplementary Figure S5 (supporting Figure 3). G129R reduced the viabilities of Ishikawa and Hec1A cells in comparison with PRL stimulation at hormone-depleted condition. Supplementary Figure S6 (supporting Figure 5). siRNAs knock down the expression of FOXO3a or EIF-4EBP1 in Ishikawa and Hec1A cells. Supplementary Figure S7 (supporting Figure 4C & 4D, Supplementary Figure S2, and Supplementary Figure S6). Uncropped western blots produced in this study.
Supplementary Table 1 from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer
Authors: Wen Yunfei , Wang Ying , Chelariu-Raicu Anca , Stur Elaine , Liu Yuan , Corvigno Sara , Bartsch Faith , Redfern Lauren , Zand Behrouz , Kang Yu , Liu Jinsong , Baggerly Keith , Sood Anil K.
Published: April 2023

Supplementary Table 1. Dataset for the reverse-phase protein array (RPPA) and processed data for Ingenuity Pathway Analysis.
Table S1, S2, S3 and S4 from Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
Authors: García-Martínez Juan Manuel , Wang Shirley , Weishaeupl Cordula , Wernitznig Andreas , Chetta Paolo , Pinto Catarina , Ho Jason , Dutcher Darrin , Gorman Philip N. , Kroe-Barrett Rachel , Rinnenthal Joerg , Giragossian Craig , Impagnatiello Maria Antonietta , Tirapu Iñigo , Hilberg Frank , Kraut Norbert , Pearson Mark , Kuenkele Klaus Peter
Published: April 2023

-S1: Evaluation of CDH17 and TRAILR2 IHC staining in hepatic metastases of colorectal cancer -S2:BI 905711 kinetic and steady-state measurements -S3: CDH17 and TRAILR2 mean fluorescence intensity, antibody binding capacity and BI 905711 / TAS266' minPOC in 24 CRC cell lines -S4: Intergroup comparison of gross pathology observations in Cynomolgus Monkey small intestine, large intestine and pancreas
Supplementary Material and Methods from Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
Authors: García-Martínez Juan Manuel , Wang Shirley , Weishaeupl Cordula , Wernitznig Andreas , Chetta Paolo , Pinto Catarina , Ho Jason , Dutcher Darrin , Gorman Philip N. , Kroe-Barrett Rachel , Rinnenthal Joerg , Giragossian Craig , Impagnatiello Maria Antonietta , Tirapu Iñigo , Hilberg Frank , Kraut Norbert , Pearson Mark , Kuenkele Klaus Peter
Published: April 2023

Supplementary Material and Methods
Figure S4 from Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
Authors: García-Martínez Juan Manuel , Wang Shirley , Weishaeupl Cordula , Wernitznig Andreas , Chetta Paolo , Pinto Catarina , Ho Jason , Dutcher Darrin , Gorman Philip N. , Kroe-Barrett Rachel , Rinnenthal Joerg , Giragossian Craig , Impagnatiello Maria Antonietta , Tirapu Iñigo , Hilberg Frank , Kraut Norbert , Pearson Mark , Kuenkele Klaus Peter
Published: April 2023

IHC for cleaved caspase-8 and cleaved caspase-3 24h after the second administration of BI 905711 in GP2d xenograft tumors.
Figure S3 from Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
Authors: García-Martínez Juan Manuel , Wang Shirley , Weishaeupl Cordula , Wernitznig Andreas , Chetta Paolo , Pinto Catarina , Ho Jason , Dutcher Darrin , Gorman Philip N. , Kroe-Barrett Rachel , Rinnenthal Joerg , Giragossian Craig , Impagnatiello Maria Antonietta , Tirapu Iñigo , Hilberg Frank , Kraut Norbert , Pearson Mark , Kuenkele Klaus Peter
Published: April 2023

CDH17 and TRAILR2 protein expression and their correlation with BI 905711 minPOC in CRC cell lines.
Supplementary Methods and Figures 1-8 from Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy
Authors: Anbil Sriram , Pigula Michael , Huang Huang-Chiao , Mallidi Srivalleesha , Broekgaarden Mans , Baglo Yan , De Silva Pushpamali , Simeone Diane M. , Mino-Kenudson Mari , Maytin Edward V. , Rizvi Imran , Hasan Tayyaba
Published: April 2023

Supplementary Methods Supplemental Figure 1: The MIA-PaCa-2 + PCAF model exhibits histologic features consistent with desmoplasia 90 days post implantation Supplemental Figure 2: 1 μM calcipitriol activates the vitamin D receptor (VDR) in cancer associated fibroblasts Supplemental Figure 3: VDAR activation + PDP enable a 75% dose reduction in nal-IRI Supplemental Figure 4: Inhibition of the CXCL12/CXCR7 by CAL+PDP is lost by day 90 post-implantation Supplemental Figure 5: Calcipotriol and photodynamic priming cytotoxicity curves Supplemental Figure 6: MRC-5 conditioned medium does not affect the baseline metabolic activity of PDAC cell lines Supplemental Figure 7: PDP increases intratumoral nal-IRI via increased vascular and parenchymal permeability Supplemental Figure 8: Treatment with CAL+PDP+5 mg/kg nal-IRI induces global transcriptomic shifts in pancreataic tumors that correlate with a less aggressive and more responsive treatment profile compared to treatment with PDP+20 mg/kg nal-IRI
Supplementary Methods from NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both In Vitro and In Vivo
Authors: Cai Yijun , Chow Jeremy P.H. , Leung Yu-On , Lu Xiaoxu , Yuen Chak-Ho , Lee Wing Lun , Chau Ka-Chun , Yang Liz L. , Wong Raymond M.H. , Lam Justin Y.T. , Chow Daniel T.L. , Chung Steven H.K. , Kwok Sui-Yi , Leung Yun-chung
Published: April 2023

Supplementary Methods
Supplementary Fig. S5 from NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both In Vitro and In Vivo
Authors: Cai Yijun , Chow Jeremy P.H. , Leung Yu-On , Lu Xiaoxu , Yuen Chak-Ho , Lee Wing Lun , Chau Ka-Chun , Yang Liz L. , Wong Raymond M.H. , Lam Justin Y.T. , Chow Daniel T.L. , Chung Steven H.K. , Kwok Sui-Yi , Leung Yun-chung
Published: April 2023

Treatment with NEI-01 observably decreased the leukemia cells as well as recovered the normal structure in bone marrow, spleen and liver from mice bearing AM5512 PDX
Supplementary Fig. S4 from NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both In Vitro and In Vivo
Authors: Cai Yijun , Chow Jeremy P.H. , Leung Yu-On , Lu Xiaoxu , Yuen Chak-Ho , Lee Wing Lun , Chau Ka-Chun , Yang Liz L. , Wong Raymond M.H. , Lam Justin Y.T. , Chow Daniel T.L. , Chung Steven H.K. , Kwok Sui-Yi , Leung Yun-chung
Published: April 2023

Treatment with NEI-01 significantly inhibited cell proliferation by induction of cell cycle arrest and apoptosis in mouse ASS1-deficient C1498 cells
Supplementary Fig. S3 from NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both In Vitro and In Vivo
Authors: Cai Yijun , Chow Jeremy P.H. , Leung Yu-On , Lu Xiaoxu , Yuen Chak-Ho , Lee Wing Lun , Chau Ka-Chun , Yang Liz L. , Wong Raymond M.H. , Lam Justin Y.T. , Chow Daniel T.L. , Chung Steven H.K. , Kwok Sui-Yi , Leung Yun-chung
Published: April 2023

ASS1 expression in AML cell lines and normal fibroblast
Supplementary Fig. S2 from NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both In Vitro and In Vivo
Authors: Cai Yijun , Chow Jeremy P.H. , Leung Yu-On , Lu Xiaoxu , Yuen Chak-Ho , Lee Wing Lun , Chau Ka-Chun , Yang Liz L. , Wong Raymond M.H. , Lam Justin Y.T. , Chow Daniel T.L. , Chung Steven H.K. , Kwok Sui-Yi , Leung Yun-chung
Published: April 2023

ASS1 expression in AML patients and its effect on survival
Supplementary Methods, Supplementary Table 1, and Supplementary Figures 1-4 from SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
Authors: Conteduca Vincenza , Ku Sheng-Yu , Puca Loredana , Slade Megan , Fernandez Luisa , Hess Judy , Bareja Rohan , Vlachostergios Panagiotis J. , Sigouros Michael , Mosquera Juan Miguel , Sboner Andrea , Nanus David M. , Elemento Olivier , Dittamore Ryan , Tagawa Scott T. , Beltran Himisha
Published: April 2023

Supplementary Information includes: Supplementary Methods, Supplementary Table 1 which shows pathologic and clinical characteristics of patient WCM1388; Supplementary Figure 1 which shows SLFN11 expression across different cancer types; Supplementary Figure 2 which shows CK vs SLFN11 expression in CTCs; Supplementary Figure 3 which shows the discordant case between CTCs and tissue mRNA; Supplementary Figure 4 which is SLFN11 knockout of organoids and response to olaparib
Supplementary Fig. S1 from NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both In Vitro and In Vivo
Authors: Cai Yijun , Chow Jeremy P.H. , Leung Yu-On , Lu Xiaoxu , Yuen Chak-Ho , Lee Wing Lun , Chau Ka-Chun , Yang Liz L. , Wong Raymond M.H. , Lam Justin Y.T. , Chow Daniel T.L. , Chung Steven H.K. , Kwok Sui-Yi , Leung Yun-chung
Published: April 2023

ASS1 expression in pan-cancer
Figure S2 from Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2
Authors: Maloney Caroline , Kallis Michelle P. , Edelman Morris , Tzanavaris Christopher , Lesser Martin , Soffer Samuel Z. , Symons Marc , Steinberg Bettie M.
Published: April 2023

Figure S2 shows that gefitinib has no effect on the size of the primary tumor.
Table S2 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

Primer sequences for qRT-PCR
Supplementary Figure 8 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

Cell viability assay using ALDH1A3 inhibitors and ALDH1A3 expression in scRNA-seq data
Supplementary Figure 7 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

Kaplan Meier survival analysis of mice using MDA-468 cells
Supplementary Figure 5 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

IHC for ALDH1A3 in a mouse BM tissues of MDA-468 cells
Figure S6 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
Authors: Ho Sun K. , Xu Zhenghai , Thakur Archana , Fox Melvin , Tan Siu Sze , DiGiammarino Enrico , Zhou Li , Sho Mien , Cairns Belinda , Zhao Vivian , Xiong Mengli , Samayoa Josue , Forsyth Charles M. , Powers David B. , Chao Debra T. , Hollenbaugh Diane , Alvarez Hamsell M. , Akamatsu Yoshiko
Published: April 2023

Combination study of anti-CD137 with anti PD-1 or anti-PD-L1
Figure S5 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
Authors: Ho Sun K. , Xu Zhenghai , Thakur Archana , Fox Melvin , Tan Siu Sze , DiGiammarino Enrico , Zhou Li , Sho Mien , Cairns Belinda , Zhao Vivian , Xiong Mengli , Samayoa Josue , Forsyth Charles M. , Powers David B. , Chao Debra T. , Hollenbaugh Diane , Alvarez Hamsell M. , Akamatsu Yoshiko
Published: April 2023

Efficacy and pharmacodynamics analysis of anti-CD137 in vivo
Supplementary Figure 3 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

IHC of BM and LM of human TNBC patients
Figure S4 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
Authors: Ho Sun K. , Xu Zhenghai , Thakur Archana , Fox Melvin , Tan Siu Sze , DiGiammarino Enrico , Zhou Li , Sho Mien , Cairns Belinda , Zhao Vivian , Xiong Mengli , Samayoa Josue , Forsyth Charles M. , Powers David B. , Chao Debra T. , Hollenbaugh Diane , Alvarez Hamsell M. , Akamatsu Yoshiko
Published: April 2023

Human T cell costimulation activity of anti-CD137
Supplementary Figure 2 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

Survival analysis of breast cancer patients
Supplementary Figure 1 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

Synthesis steps of MF-7 and GA11
Figure S2 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
Authors: Ho Sun K. , Xu Zhenghai , Thakur Archana , Fox Melvin , Tan Siu Sze , DiGiammarino Enrico , Zhou Li , Sho Mien , Cairns Belinda , Zhao Vivian , Xiong Mengli , Samayoa Josue , Forsyth Charles M. , Powers David B. , Chao Debra T. , Hollenbaugh Diane , Alvarez Hamsell M. , Akamatsu Yoshiko
Published: April 2023

Serum concentration of mAbs after the last dose
Supplementary Data from An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models
Authors: Yu Shang-Fan , Lee Donna W. , Zheng Bing , del Rosario Geoffrey , Leipold Douglas , Booler Helen , Zhong Fiona , Carrasco-Triguero Montserrat , Hong Kyu , Yan Peter , Rowntree Rebecca K. , Schutten Melissa M. , Pillow Thomas , Sadowsky Jack D. , Dragovich Peter S. , Polson Andrew G.
Published: April 2023

Supplementary Data
Supplementary table 1 and figures 1-4 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types
Authors: Topham James T. , Titmuss Emma , Pleasance Erin D. , Williamson Laura M. , Karasinska Joanna M. , Culibrk Luka , Lee Michael K.C. , Mendis Shehara , Denroche Robert E. , Jang Gun-Ho , Kalloger Steve E. , Wong Hui-Li , Moore Richard A. , Mungall Andrew J. , O'Kane Grainne M. , Knox Jennifer J. , Gallinger Steven , Loree Jonathan M. , Mager Dixie L. , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Schaeffer David F. , Renouf Daniel J.
Published: April 2023

Supplemental Table S1 lists clinical characteristics for the study cohort. Figure S1 depicts results of batch correction. Figures S2 and S3 show comparisons between ERV levels and tumor content. Figure S4 shows ERV levels across different biopsy sites.
Supplementary Figures from Hsp90 Inhibitor STA9090 Sensitizes Hepatocellular Carcinoma to Hyperthermia-Induced DNA Damage by Suppressing DNA-PKcs Protein Stability and mRNA Transcription
Authors: Liu Lixia , Deng Yaotang , Zheng Zhenming , Deng Zihao , Zhang Jinxin , Li Jieyou , Liang Manfeng , Zhou Xueqiong , Tan Wenchong , Yang Hongjun , Neckers Leonard M. , Zou Fei , Chen Xuemei
Published: April 2023

Supplemental Figures 1-7 Merged PDF